ImClone to Eli Lilly LLY in 2008, and we think his appointment could reinvigorate takeover speculation for Dendreon. The firm ranked No. 4 on Morningstar's Biotech Takeover List last year. LaurenMigliore also contributed to this note.
Independent. Insightful. Trusted. Morningstar provides stock market analysis; equity, mutual fund, and ETF research, ratings, and picks; portfolio tools; and option, hedge fund, IRA, 401k, and 529 plan research. Our reliable data and analysis can help both experienced enthusiasts and newcomers.